Skip to Main Content

Inovio Pharmaceuticals, Inc. Securities Class Action

View Complaint
COMPANY         Inovio Pharmaceuticals, Inc.
COURT United States District Court for the Eastern District of Pennsylvania
CASE NUMBER 20-cv-01402
JUDGE The Honorable Gerald John Pappert
CLASS PERIOD February 14, 2020 - August 10, 2020
SECURITY TYPE  Common Stock

Case Background:

On March 12, 2020, the initial complaint in this securities class action was filed against Inovio Pharmaceuticals, Inc. (“Inovio” or the “Company”) and certain of Inovio’s directors and officers, asserting violations of Sections 10(b) and 20(a) of the Securities Exchange Act. This is a federal securities fraud class action brought on behalf of all persons or entities who purchased or acquired Inovio common stock between February 14, 2020 and August 10, 2020, (the “Class Period”) both dates inclusive.

The complaint alleges that during the Class Period, Inovio made misleading statements about the Company’s development of a purported vaccine for the novel coronavirus (“COVID -19”). Specifically, the complaint alleges that Defendants capitalized on widespread COVID-19 fears by falsely claiming that Inovio had developed a vaccine for COVID-19.  The complaint alleges that Inovio’s stock price rose significantly in response to this disclosure but plummeted when another company exposed Inovio’s misstatements and called for an investigation by the U.S. Securities and Exchange Commission into the claims.

Current Status of Case:

On September 21, 2020, Lead Plaintiff filed an amended complaint (the “Complaint”). On February 16, 2021, the Court issued an Order granting in part and denying in part Defendants’ Motion to Dismiss the Complaint. On February 1, 2023, the Court issued an Order approving the settlement of this action.  This action has concluded.  

The deadline to file a claim is December 19, 2022.  Please note that Kessler Topaz did not file a claim on your behalf. You may find additional information regarding the terms of the settlement and claim filing process at www.InovioSecuritiesLitigation.com  or by calling Gilardi & Co. at 1-866-809-3338. 

If you wish to discuss this action or have any questions concerning this notice or your rights or interests with respect to these matters, please contact Kessler Topaz Meltzer & Check, LLP: Jon Naji, Esq. (484) 270-1453; or via e-mail at info@ktmc.com. If you would like additional information about the suit, please click on the link "Submit Your Information" above and fill out the form as promptly as possible.

Please complete this form relating to your transactions for Inovio Pharmaceuticals, Inc. (Nasdaq: INO) common stock between February 14, 2020 and August 10, 2020, inclusive (the “Class Period”).

You may also contact Jon Naji, Esq. at (484) 270-1453; or you may submit your information via email at info@ktmc.com, or you may click here to print a PDF of this form.

SUBMIT YOUR INFORMATION
* Denotes required field
Date
# of Shares
Price per Share
Date
Principal Amount
Amount Paid
Series or CUSIP
Date
# of Contracts
Price per Contract
Exercise Price
Expiration Date
Did you purchase shares of Inovio Pharmaceuticals, Inc. prior to the Class Period?
Are you a current or former employee of Inovio Pharmaceuticals, Inc. ?
The submission of this form does not create an attorney-client relationship, nor an obligation on the part of Kessler Topaz or you to file a lead plaintiff motion in this matter. Any information you submit will be maintained as confidential. If Kessler Topaz, in its sole discretion, believes that you might be an appropriate lead plaintiff candidate, Kessler Topaz will contact you to discuss the matter and whether to establish an attorney client relationship. By signing this form you are authorizing us to contact you regarding this case and/or future cases.
I agree to the KTMC disclaimer
I would like to receive new case alerts by email